{"classes":[{"categories":[{"measurements":[{"comment":"Due to lack of events, this outcome measure was not analyzed.","groupId":"OG000","value":"NA"},{"comment":"Due to lack of events, this outcome measure was not analyzed.","groupId":"OG001","value":"NA"},{"comment":"Due to lack of events, this outcome measure was not analyzed.","groupId":"OG002","value":"NA"},{"comment":"Due to lack of events, this outcome measure was not analyzed.","groupId":"OG003","value":"NA"},{"comment":"Due to lack of events, this outcome measure was not analyzed.","groupId":"OG004","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier.","groups":[{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG000","title":"Dose Escalation: 3 x 10^7 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG001","title":"Dose Escalation: 1 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG002","title":"Dose Escalation: 3 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^9 autologous anti-BCMA CAR T cells on Day 0.","id":"OG003","title":"Dose Escalation: 1 x 10^9 KITE-585"},{"description":"RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \\[Grade 2 chronic kidney disease\\]) received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 24 mg/m\\^2/day IV infusion for 3 days followed by single infusion of KITE-585 at a tolerable dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG004","title":"Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585"}],"paramType":"NUMBER","populationDescription":"Participants in the Safety Analysis Set were to be analyzed. Estimates of the proportion of participants who have not required additional treatment for progressive multiple myeloma at selected time points were to be provided. As per changes in planned analysis, this outcome measure could not be analyzed at the data cutoff date due to a lack of events. Kite/Gilead did not collect data to analyze TTNT after the data cutoff date.","reportingStatus":"POSTED","timeFrame":"From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)","title":"Time to Next Treatment (TTNT)","type":"SECONDARY","unitOfMeasure":"months"}